Adynxx

(ADYX, NASDAQ)

$0.12

+$0.00
(+0.03%)
PE Ratio
0.00
EPS
-$1.75
Market Cap
$662K
52 Week Range
$0.05 - $1.74
Operating Margin
0.00%
Dividend & Yield
$0.00 (300%)
Volume
NaN
Rev. per Share
$0.00

About Adynxx

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Earnings

News about Adynxx

Adynxx

Type
Sector
Healthcare
Industry
Biotechnology
About kinfo
Kinfo is an app for DIY traders and investors. Kinfo tracks your trading performance and lets you compare measurable performance metrics against other traders. Kinfo works for day trading, swing trading and longer holding periods. By tracking portfolio performance kinfo allows traders to learn, find inspiration and gain confidence.
Get Social
Download the App